CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of “Moderate Buy” from Analysts

CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) has earned an average rating of “Moderate Buy” from the twenty brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $116.19.

CRSP has been the topic of a number of recent research reports. Citigroup upped their target price on shares of CRISPR Therapeutics from $53.00 to $83.00 and gave the stock a “neutral” rating in a research report on Tuesday. Chardan Capital reduced their target price on shares of CRISPR Therapeutics from $168.00 to $164.00 and set a “buy” rating on the stock in a research report on Wednesday, June 22nd. Needham & Company LLC reduced their target price on shares of CRISPR Therapeutics from $170.00 to $122.00 in a research report on Friday, May 13th. The Goldman Sachs Group reduced their target price on shares of CRISPR Therapeutics from $52.00 to $46.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 24th. Finally, Credit Suisse Group initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, April 28th. They set a “neutral” rating and a $78.00 price objective on the stock.

CRISPR Therapeutics Price Performance

CRSP stock opened at $81.40 on Friday. CRISPR Therapeutics has a one year low of $42.51 and a one year high of $142.64. The stock has a market cap of $6.30 billion, a PE ratio of 22.55 and a beta of 1.93. The firm has a 50 day simple moving average of $70.64 and a two-hundred day simple moving average of $63.10.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last announced its quarterly earnings data on Monday, May 9th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.91) by ($0.41). CRISPR Therapeutics had a net margin of 34.04% and a return on equity of 12.77%. The business had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $2.45 million. During the same period last year, the company posted ($1.51) EPS. CRISPR Therapeutics’s revenue for the quarter was up 74.4% on a year-over-year basis. On average, research analysts expect that CRISPR Therapeutics will post -8.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 25,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $75.91, for a total transaction of $1,897,750.00. Following the sale, the chief executive officer now owns 290,279 shares in the company, valued at $22,035,078.89. The transaction was disclosed in a document filed with the SEC, which is available at this link. 10.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. National Bank of Canada FI bought a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $88,000. State of New Jersey Common Pension Fund D raised its holdings in shares of CRISPR Therapeutics by 1.7% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 39,141 shares of the company’s stock valued at $2,966,000 after acquiring an additional 652 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $2,135,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of CRISPR Therapeutics by 16.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 53,891 shares of the company’s stock valued at $4,084,000 after acquiring an additional 7,627 shares in the last quarter. Finally, FDx Advisors Inc. raised its holdings in shares of CRISPR Therapeutics by 16.6% in the fourth quarter. FDx Advisors Inc. now owns 7,098 shares of the company’s stock valued at $538,000 after acquiring an additional 1,013 shares in the last quarter. 56.12% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles

Analyst Recommendations for CRISPR Therapeutics (NASDAQ:CRSP)

Want More Great Investing Ideas?

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.